{
    "Trade/Device Name(s)": [
        "Vysis EGR1 FISH Probe Kit",
        "Vysis LSI EGR1 SpectrumOrange/D5S23, D5S721 SpectrumGreen Probes"
    ],
    "Submitter Information": "Abbott Molecular Inc.",
    "510(k) Number": "K091960",
    "Predicate Device Reference 510(k) Number(s)": [
        "K100015"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OWK"
    ],
    "Summary Letter Date": "February 24, 2011",
    "Summary Letter Received Date": "February 25, 2011",
    "Submission Date": "August 25, 2011",
    "Regulation Number(s)": [
        "21 CFR 866.6040"
    ],
    "Regulation Name(s)": [
        "Gene expression profiling test system for breast cancer prognosis"
    ],
    "Analyte Class(es)": [
        "genetic molecular",
        "hematology"
    ],
    "Analyte(s)": [
        "EGR1 gene (5q31 deletion)"
    ],
    "Specimen Type(s)": [
        "Bone marrow"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Fluorescence microscope"
    ],
    "Method(s)/Technology(ies)": [
        "Fluorescence in situ hybridization (FISH)"
    ],
    "Methodologies": [
        "FISH DNA probe hybridization"
    ],
    "Submission Type(s)": [
        "Probe Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Vysis EGR1 FISH Probe Kit using FISH DNA probes to detect EGR1 (5q31) deletions in bone marrow for AML prognosis",
    "Indications for Use Summary": "Intended to detect deletion of the LSI EGR1 probe target on chromosome 5q in bone marrow specimens as an aid in determining prognosis at AML diagnosis, used in conjunction with cytogenetics and other clinical information.",
    "fda_folder": "Immunology"
}